Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 10;184(2):460–475.e21. doi: 10.1016/j.cell.2020.11.007

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Figure S1 — Baricitinib was well-tolerated and detectable in the central nervous system in SARS-CoV-2-infected RMs, related to Figure 1

(A) Left, concentration of baricitinib 2 hours after dosing in brain and CSF and, right, 24 hours after dosing in CSF.

(B–D) Longitudinal frequency of (B) monocytes, (C) neutrophils, and (D) lymphocytes in blood of SARS-CoV-2 infected RMs.

(E–H) In (E), red blood cell counts (RBC), (F) hematocrit (HCT), (G) hemoglobin (HGB) and (H) alkaline phosphatase (ALP) levels were analyzed throughout the study.

(I) Longitudinal rectal temperatures. Different symbols represent individual animals. Bold lines represent the average of the baricitinib treated group (blue), and the untreated group (red).